#ACR19 ABST #1590 -3 RCTs show anti-TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials @DrPetryna